GlassScriptPhysician profile
Jeffrey M Rosenberg
NPI 1801902911
$44,100.54
in general payments reported to CMS, 2019-2025
64 companies · $2,378 in 2025
The $2,378 reported for 2025 was more than what 82% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,341 · 2020: $5,058 · 2021: $6,281 · 2022: $6,947 · 2023: $8,587 · 2024: $7,508 · 2025: $2,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $8,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,450.00 |
| Food and Beverage | $8,022.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21,106.28 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, General - Pain Management |
| Nutech Spine, INC. | $5,600.00 | 2021-2022 | |
| Abbott Laboratories | $2,109.07 | 2019-2025 | Proclaim |
| Vertiflex, INC. | $1,774.13 | 2019 | |
| Abbvie INC. | $1,657.31 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Nevro Corp. | $1,638.86 | 2019-2024 | Senza |
| Collegium Pharmaceutical, INC. | $986.69 | 2019-2025 | Belbuca, Xtampza |
| Allergan, INC. | $771.35 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $669.39 | 2019-2023 | Ztlido |
| Medtronic, INC. | $643.39 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Mdd US Operations, LLC | $537.24 | 2019-2020 | |
| Amgen INC. | $500.05 | 2019-2021 | |
| Tersera Therapeutics LLC | $493.21 | 2019-2025 | Prialt |
| Relievant Medsystems, INC. | $461.96 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $443.63 | 2019-2024 | Relistor |
Show all 63 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.